Abstract
OBJECTIVE: The predictive value of intratumoral microbiota for the efficacy of neoadjuvant immunochemotherapy, as well as the changes in microbiota before and after treatment, has remained largely unexplored. METHODS: We employed 2bRAD sequencing for Microbiome (2bRAD-M) to analyze 42 specimens from patients with locally advanced oral squamous cell carcinoma (OSCC), focusing on trends in intratumoral microbiota changes before and after neoadjuvant immunochemotherapy, and predicting responses to the treatment. RESULTS: (1) There was no significant difference between the MPR_before group and nMPR_before group in terms of α diversity and β diversity at baseline, but Ralstonia_sp.000620465, Methylobacterium_rhodesianum, Methylobacterium_jeotgali, RH_AL1_sp.901457705, Rothia_sp.002418375, and Rothia_mucilaginosa_A, which were enriched in immune-related signaling pathways, were significantly more abundant in the nMPR_before group and could predict the efficacy of neoadjuvant immunotherapy (AUC=0.74) . (2) Importantly, both the α and β diversity of intratumoral microbiota significantly decreased after neoadjuvant immunochemotherapy, regardless of whether we compared the MPR_before group with MPR_after group or the nMPR_before group with nMPR_after group. (3) The abundance of Deinococcus_geothermalis was significantly higher in the nMPR_after group, while Burkholderia_vietnamiensis was enriched in the MPR_after group. These differential microbial populations between the nMPR_after group and MPR_after group were enriched in metabolism-related pathways such as carbon fixation in photosynthetic organisms, taurine and hypotaurine metabolism, and genetic information processing pathways, including homologous recombination and DNA replication. CONCLUSION: Neoadjuvant immunochemotherapy markedly alters intratumoral microbiota diversity. Baseline and post-treatment microbiota differences between MPR and nMPR groups implicate specific signaling pathways that may influence treatment efficacy in locally advanced OSCC.